Alpha1-Antitrypsin Deficiency AAT is a protease inhibitor targeting neutrophil elastase. It
prevents the destruction of tissue, particularly in the lung, from elastase activity. AAT …

Worldwide, each year over 30,000 patients undergo an allogeneic hema-topoietic stem cell
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …

Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after
allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet …

Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic
hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and …

Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse
complications of allogeneic transplantation which still cause substantial morbidity and …

Summary Alpha-1 antitrypsin deficiency (AATD) arises from mutations in the SERPINA1
gene encoding alpha-1 antitrypsin (AAT) that lead to AAT retention in the endoplasmic …

Elastase is a proteolytic enzyme belonging to the family of hydrolases produced by human
neutrophils, monocytes, macrophages, and endothelial cells. Human neutrophil elastase is …

Alpha-1 antitrypsin (AAT) is the canonical serine protease inhibitor of neutrophil-derived
proteases and can modulate innate immune mechanisms through its anti-inflammatory …

Use of haematopoietic cell transplantation (HCT) in the treatment of haematologic and
neoplastic diseases may lead to life‐threatening complications that cause substantial …

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell
transplantation (HCT) is a primary cause of nonrelapse mortality and a major barrier to …